IISs are research studies that are conceived, executed, and reported by the Investigator independent of SERB Pharmaceuticals. As such, the Investigator takes full responsibility for the design, conduct, analyses, safety, regulatory and publication activities of the study. It is the responsibility of the Investigator to comply with, all applicable laws, regulations, guidelines and industry codes governing the conduct of IISs (e.g. ICH-GCP).

SERB, operating as BTG Pharmaceuticals in the US, is committed to supporting independent research in the form of IISs that further the understanding of diseases and their treatment with the ultimate goal of helping patients. SERB can provide its pharmaceutical products and/or financial support for IISs that are approved through SERB’s review committee.

Our Process

If you are a Healthcare Professional with an IIS proposal, the first step is to discuss your proposal with your local SERB Medical Liaison/Medical Advisor (ML/MA) who will provide you with a “Concept Proposal Form” for completion and submission. If you are unsure who your ML/MA is, contact us at iismanagement@serb.com, and someone from SERB will be in touch to discuss your proposal.

The IIS process continues as follows:

Your IIS proposal will be reviewed by the SERB review committee and will be assessed against criteria including:

• Scientific robustness, safety and ethical integrity
• Alignment with the strategy of SERB

Investigator’s Obligation to SERB Pharmaceuticals

As the Investigator, you agree to provide SERB a copy of selected documents (as applicable) prior to commencement of the study. These documents include:

• Ethics Committee / Institutional Review Board (IRB) and Regulatory Authority approval letter (where appropriate) for the IIS
• Copy of Ethics Committee / IRB approved protocol and consent form
• An up to date and signed copy of your CV
• Fully executed legal agreement

During the study, SERB requires that safety and adverse events be reported to appropriate bodies as directed. As the Investigator, you must also notify SERB should there be any study document amendments, audits, patient safety concerns or issues that may significantly hinder progress, execution, or completion of the IIS as planned. Any congress abstract submissions and/or journal publications resulting from the IIS must be submitted to SERB for review prior to submission for peer review. A final study report or publication summarising all study results must be submitted to SERB in a timely manner regardless of study outcome.

SERB’s Commitment to the Investigator

At SERB Pharmaceuticals we aim to provide you with timely feedback and a decision on whether we will support your IIS. Review meetings are held monthly, and once reviewed we commit to providing you with feedback as soon as possible. We receive many proposals and not all are approved; each proposal is evaluated on its own merit.

If approved, a provision of support will be defined and documented in a legal agreement, which includes the roles and responsibilities of each party. Agreed financial and product support is linked with predefined milestones and will be paid when milestones are achieved.

Support of an IIS is not intended to encourage the prescription, supply, administration, recommendation, purchase or sale of any SERB product. We are committed to both data and financial transparency. To ensure we continues to be compliant with relevant laws and regulations, all transfers of value (i.e. payments and product provision) are tracked and reported in accordance with the relevant local regulations. We encourage all Investigators to also share and report any support provided to them when required, and to share the results of their research.